Literature DB >> 22687502

Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.

Warren E Rose1, Michael Fallon, John J M Moran, Joshua P Vanderloo.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) isolates that are susceptible to vancomycin but are tolerant to its killing effect may present a potential challenge for effective treatment. This study compared the microbiologic characteristics of clinical vancomycin-tolerant (VT-MRSA) and vancomycin-susceptible (VS-MRSA) strains using phenotypic and gene regulation studies. MRSA isolates collected from vancomycin-treated patients with bacteremia over a 5-year period were analyzed for vancomycin, daptomycin, and telavancin susceptibility, as well as accessory gene regulator (agr) group and function. Vancomycin tolerance was defined by a minimum bactericidal concentration (MBC)/minimum inhibitor concentration (MIC) ratio of ≥32 mg/liter. VT-MRSA isolates were compared to VS-MRSA isolates for differences in antimicrobial susceptibility, time-kill activity, and gene expression of key cell envelope response genes vraSR, dltA, and mprF. All 115 isolates evaluated were susceptible to vancomycin, daptomycin, and telavancin. Seven isolates (6%) were VT-MRSA. agr group II was more prevalent in isolates with vancomycin MBC/MIC ratios of ≥8. In time-kill analyses, VT-MRSA had reduced vancomycin killing, but daptomycin and telavancin activities were maintained. Significantly greater gene expression was observed in VT-MRSA after 72 h of subinhibitory antibiotic exposures. Vancomycin most notably increased vraSR expression (P = 0.002 versus VS-MRSA strains). Daptomycin and telavancin increased expression of all genes studied, most significantly mprF expression (P < 0.001). Longer durations of antibiotic exposure (72 h versus 24 h) resulted in substantial increases in gene expression in VT-MRSA. Although the clinical impact of VT-MRSA is not fully recognized, these data suggest that VT-MRSA strains, while still susceptible, have altered gene regulation to adapt to the antimicrobial effects of glyco- and lipopeptides that may emerge during prolonged durations of exposure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687502      PMCID: PMC3421561          DOI: 10.1128/AAC.00676-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; James O Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Wei Gao; Keryn J Christiansen; Geoffrey W Coombs; Paul D R Johnson; Benjamin P Howden
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

3.  VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.

Authors:  Shrenik Mehta; Arabela X Cuirolo; Konrad B Plata; Sarah Riosa; Jared A Silverman; Aileen Rubio; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.

Authors:  Adrien Fischer; Soo-Jin Yang; Arnold S Bayer; Ali R Vaezzadeh; Sébastien Herzig; Ludwig Stenz; Myriam Girard; George Sakoulas; Alexander Scherl; Michael R Yeaman; Richard A Proctor; Jacques Schrenzel; Patrice François
Journal:  J Antimicrob Chemother       Date:  2011-05-28       Impact factor: 5.790

5.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Christine Wennersten; Lata Venkataraman; Richard P Novick; Howard S Gold
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.

Authors:  Ravina Kullar; Susan L Davis; Donald P Levine; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

8.  Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Warren E Rose; Ryan M Knier; Paul R Hutson
Journal:  J Antimicrob Chemother       Date:  2010-08-06       Impact factor: 5.790

9.  Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.

Authors:  Viviana Cafiso; Taschia Bertuccio; Daniela Spina; Simona Purrello; Floriana Campanile; Cinzia Di Pietro; Michele Purrello; Stefania Stefani
Journal:  PLoS One       Date:  2012-01-09       Impact factor: 3.240

10.  The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.

Authors:  Hitoshi Honda; Christopher D Doern; Wm Michael-Dunne; David K Warren
Journal:  BMC Infect Dis       Date:  2011-12-05       Impact factor: 3.090

View more
  13 in total

1.  In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.

Authors:  Abrar K Thabit; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

2.  Small cationic antimicrobial peptides delocalize peripheral membrane proteins.

Authors:  Michaela Wenzel; Alina Iulia Chiriac; Andreas Otto; Dagmar Zweytick; Caroline May; Catherine Schumacher; Ronald Gust; H Bauke Albada; Maya Penkova; Ute Krämer; Ralf Erdmann; Nils Metzler-Nolte; Suzana K Straus; Erhard Bremer; Dörte Becher; Heike Brötz-Oesterhelt; Hans-Georg Sahl; Julia Elisabeth Bandow
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

Review 3.  Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci.

Authors:  William R Miller; Arnold S Bayer; Cesar A Arias
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

4.  Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.

Authors:  Nicholas S Britt; Nimish Patel; Theresa I Shireman; Wissam I El Atrouni; Rebecca T Horvat; Molly E Steed
Journal:  J Antimicrob Chemother       Date:  2016-12-20       Impact factor: 5.790

5.  Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Nicholas S Britt; Nimish Patel; Rebecca T Horvat; Molly E Steed
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

6.  Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus: In Vitro, Ex Vivo, and In Vivo Metrics.

Authors:  Nagendra N Mishra; Cassandra Lew; Wessam Abdelhady; Christian K Lapitan; Richard A Proctor; Warren E Rose; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

7.  Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickening.

Authors:  Vicenta Cázares-Domínguez; Ariadnna Cruz-Córdova; Sara A Ochoa; Gerardo Escalona; José Arellano-Galindo; Alejandra Rodríguez-Leviz; Rigoberto Hernández-Castro; Edgar O López-Villegas; Juan Xicohtencatl-Cortes
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

8.  In vitro inhibitory and cytotoxic activity of MFM 501, a novel codonopsinine derivative, against Methicillin-Resistant Staphylococcus aureus clinical isolates.

Authors:  Saiful Azmi Johari; Mastura Mohtar; Sharifah Aminah Syed Mohammad; Rohana Sahdan; Zurina Shaameri; Ahmad Sazali Hamzah; Mohd Fazli Mohammat
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

9.  β-Lactam-Induced Cell Envelope Adaptations, Not Solely Enhanced Daptomycin Binding, Underlie Daptomycin-β-Lactam Synergy in Methicillin-Resistant Staphylococcus aureus.

Authors:  Cassandra Lew; Nagendra N Mishra; Arnold S Bayer; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 10.  New antibiotics for bad bugs: where are we?

Authors:  Matteo Bassetti; Maria Merelli; Chiara Temperoni; Augusta Astilean
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-08-28       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.